Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
80
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study

Da Peng1 Department of Oncology, Affiliated Qingdao Central Hospital, Qingdao University, Qingdao, Shandong, People’s Republic of China
,
Dongfeng Shan2 The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People’s Republic of China
,
Chengcheng Dai1 Department of Oncology, Affiliated Qingdao Central Hospital, Qingdao University, Qingdao, Shandong, People’s Republic of China
,
Jie Li3 Department of Oncology, Jiaozhou Central Hospital, Jiaozhou, People’s Republic of China
,
Zifan Wang1 Department of Oncology, Affiliated Qingdao Central Hospital, Qingdao University, Qingdao, Shandong, People’s Republic of China
,
Ziyi Huang1 Department of Oncology, Affiliated Qingdao Central Hospital, Qingdao University, Qingdao, Shandong, People’s Republic of China
,
Rui Peng1 Department of Oncology, Affiliated Qingdao Central Hospital, Qingdao University, Qingdao, Shandong, People’s Republic of China
,
Peng Zhao4 Biotherapy Center, Affiliated Qingdao Central Hospital, Qingdao University, Qingdao, Shandong, People's Republic of ChinaCorrespondence[email protected]
&
Xuezhen Ma1 Department of Oncology, Affiliated Qingdao Central Hospital, Qingdao University, Qingdao, Shandong, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 2033-2039 | Published online: 26 Feb 2021

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Qianfei Liu, Liping Tan, Jianbo He, Ruiling Ning, Aiping Zeng & Yilin Chen. (2023) Prognostic Significance of Pretreatment Plasma D-dimer Levels in EGFR-Positive Advanced Non-Small Cell Lung Cancer Patients Receiving Osimertinib: A Multicentre Retrospective Study. International Journal of General Medicine 16, pages 5481-5491.
Read now

Articles from other publishers (7)

Yuenan Wang, Huanhuan Zhang, Yuxia Zou, Xueru Ren, Hanqi Wang, Rubing Bai, Ke Xu, Yehong Xu & Zhihong Zhang. (2023) Real‐world data on efficacy and safety of osimertinib in non‐small cell lung cancer patients with EGFR T790M mutation detected by first and repeat rebiopsy. Asia-Pacific Journal of Clinical Oncology 19:6, pages 715-722.
Crossref
Qing Zhou, He-Long Zhang, Li-Yan Jiang, Yuan-Kai Shi, Yuan Chen, Jin-Ming Yu, Cai-Cun Zhou, Yong He, Yan-Ping Hu, Zong-An Liang, Yue-Yin Pan, Wen-Lei Zhuo, Yong Song, Gang Wu, Gong-Yan Chen, You Lu, Cui-Ying Zhang, Yi-Ping Zhang, Ying Cheng, Shun Lu, Chang-Li Wang, Jian-Ying Zhou, Yun-Peng Liu, Jian-Xing He, Jie Wang & Yi-Long Wu. (2023) Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study. Journal of Cancer Research and Clinical Oncology 149:12, pages 10771-10780.
Crossref
Hye Sook Kim, Kun Young Lim, Soo‐Hyun Lee, Hyae Young Kim, Youngjoo Lee & Ji‐Youn Han. (2023) Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer . Cancer Medicine 12:11, pages 12285-12298.
Crossref
Shiyu Li, Shuangli Zhu, Hongqu Wei, Pengfei Zhu, Ying Jiao, Ming Yi, Juejun Gong, Kun Zheng & Li Zhang. (2022) The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC. Biomedicine & Pharmacotherapy 156, pages 113959.
Crossref
Xin Tang, Yuan Li, Wen-lei Qian, Wei-feng Yan, Tong Pang, You-ling Gong & Zhi-gang Yang. (2021) A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study. Journal of Cancer Research and Clinical Oncology 148:9, pages 2475-2486.
Crossref
Mutlu Hizal, Burak Bilgin, Nail Paksoy, Özgür Açıkgöz, Ahmet Sezer, Mustafa Gürbüz, Naziye Ak, Şebnem Yücel, Murat Ayhan, Cihan Erol, Aykut Demirkıran, Nil Molinas Mandel, Abdallah Shbair, İvo Gökmen, Tuğba Başoğlu, Semra Paydaş, Atike Gökçen Demiray, Yakup İriağaç, Teoman Şakalar, Esra Zeynelgil, Ali Murat Tatlı, Aykut Bahçeci, Deniz Can Güven, Burcu Caner, Alper Can, Ahmet Gülmez, Yusuf Karakaş, Bülent Yalçın, Ahmet Demirkazık, Ahmet Bilici, Adnan Aydıner, Perran Fulden Yumuk & Mehmet Ali Nahit Şendur. (2021) The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. Journal of Cancer Research and Clinical Oncology 148:6, pages 1501-1508.
Crossref
. (2021) Osimertinib. Reactions Weekly 1853:1, pages 374-374.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.